Application of candesartan cilexetil or pharmaceutically acceptable salt thereof in preparation of drug for preventing and/or treating COVID-19

The invention discloses an application of candesartan cilexetil or a pharmaceutically acceptable salt thereof in preparation of a drug for preventing and/or treating COVID-19. The candesartan cilexetil and hydrolysate candesartan have stronger binding strength with SARS-CoV-2 target 3CL hydrolase (MPro) that causes inflammation in the lung, and can significantly inhibit the activity of the 3CL hydrolase, wherein the IC50 of the candesartan cilexetil and the hydrolysate candesartan against the 3CL hydrolase (Mpro) is 2.78+/-0.31 [mu]M and 9.45+/-0.73 [mu]M, respectively, and the results indicate that the candesartan cilexetil and the hydrolysate candesartan have the effect of preventing and treating pneumonia caused by the SARS-CoV-2, and can be used to prepare an anti-pneumonia drug for application.